Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0
Sign in

SRR5088913

e12c08e3-c1a0-5db8-89b5-d4a2f216562d

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
cancer_type_detailed
subtype

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • INTERFERON_ALPHA_RESPONSE+0.300
  • MYOGENESIS+0.300
  • UV_RESPONSE_DN+0.200
  • INTERFERON_GAMMA_RESPONSE+0.100
  • KRAS_SIGNALING_DN+0.100
  • SPERMATOGENESIS+0.100
  • ALLOGRAFT_REJECTION+0.000
  • ANDROGEN_RESPONSE+0.000
  • HEDGEHOG_SIGNALING+0.000
  • HEME_METABOLISM+0.000

Top 10 suppressed

  • E2F_TARGETS-0.500
  • G2M_CHECKPOINT-0.500
  • ANGIOGENESIS-0.400
  • CHOLESTEROL_HOMEOSTASIS-0.400
  • DNA_REPAIR-0.400
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
  • MTORC1_SIGNALING-0.400
  • MYC_TARGETS_V2-0.400
  • COAGULATION-0.300
  • GLYCOLYSIS-0.300

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR11296732
colon-landscapes@1
0.845
2SAMN03290914
melanoma-umap@29
0.840
3SRR4195656
colon-landscapes@1
0.832
4C3N-03057
lung-landscapes@6
cohortA10.825
5C3N-03054
lung-landscapes@6
cohortA10.820
6MDT-AP-0810
medullo-epn-umap@date-based
MedMedulloblastoma0.820
7TCGA-NJ-A55A-01A-11R-A262-07
lung-landscapes@6
cohortA10.818
8C3N-01799
lung-landscapes@6
cohortA10.817
9SRR8943010
bladder-landscape@3
0.817
10SRR12696737
melanoma-umap@29
0.817

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 6 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INTERFERON_ALPHA_RESPONSE0.300Inavolisib— uncovered
MYOGENESIS0.300Inavolisib— uncovered
UV_RESPONSE_DN0.200Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.100Idelalisib— uncovered
KRAS_SIGNALING_DN0.100Remibrutinib— uncovered
SPERMATOGENESIS0.100Inavolisib— uncovered